SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Phase 2

Completed

• Conditions: Overactive Bladder (OAB)

• Registration Number: NCT00507169
• Lead Sponsor: Salvat

Brief Summary

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09
• Study First Submitted: 2007-07-25
• Study First Submitted QC: 2007-07-25
• Study First Posted: 2007-07-26
• Primary Completion: 2007-09
• Study Completion: 2007-09
• Status Verified: 2011-06
• Last Update Submitted: 2011-06-07
• Last Update Posted: 2011-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria

• Pregnant and breastfeeding women
• Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL